Growing adoption of high-content screening techniques in drug discovery and rising incidence of cancer primarily drives the market for live cell imaging. The growth in research funding and rising government funding and investment in regenerative medicine research will also support the market growth in the coming years. However, the high cost of high-content screening systems is limiting the overall adoption of these products. 

 

The COVID-19 pandemic has resulted in a tremendous increase in the burden on healthcare organizations across the globe. According to the WHO, as of September 29, 2020, there were 33,249,563 confirmed cases of COVID-19, including 1,000,040 deaths, with the highest number of deaths in the Americas, followed by Europe and Southeast Asia.  

 

Currently, no effective treatment for COVID-19 is available in the form of vaccines or antiviral drugs, and patients are currently treated symptomatically. According to the WHO, there are 70 vaccine candidates under development, and three candidates are already being tested in human trials. 

 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483 

 

74d5b2a053c0eeb95517285fd92ec1b1.jpg

The normalization of the global economy will slowly increase the demand for live cell imaging systems in non-COVID-related research activity labs, leading to market growth from the first quarter of 2021. Furthermore, players operating in the market are altering their strategies, for both long-term and short-term growth, by tapping the research market and developing innovative products to combat the pandemic. 

 

The traditional method of toxicity and drug safety studies involves the screening of large libraries through high-throughput screening. This method is expensive, has a low success rate, and is resource- and time-consuming. 

 

The use of HCS makes the drug development process more time- and cost-efficient. Owing to these factors, the adoption of high-content screening for toxicity studies is expected to increase during the forecast period. This, in turn, is expected to drive market growth as live cell imaging is used in HCS to identify meaningful information from complex systems such as in vitro, in vivo, and ex vivo systems. 

 

Key Market Players in Live Cell Imaging

The leading players in this market include Danaher Corporation (US), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer, Inc. (US), GE Healthcare (US), Bruker Corporation (US), Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), Oxford Instruments (UK)